These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Targeting KRAS mutant lung cancer: light at the end of the tunnel. Drosten M; Barbacid M Mol Oncol; 2022 Mar; 16(5):1057-1071. PubMed ID: 34951114 [TBL] [Abstract][Full Text] [Related]
5. FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. Morel M; Long W Mol Oncol; 2024 Mar; 18(3):762-777. PubMed ID: 37983945 [TBL] [Abstract][Full Text] [Related]
6. A saturation mutagenesis screen uncovers resistant and sensitizing secondary Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904 [TBL] [Abstract][Full Text] [Related]
7. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049 [TBL] [Abstract][Full Text] [Related]
10. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Hofmann MH; Gerlach D; Misale S; Petronczki M; Kraut N Cancer Discov; 2022 Apr; 12(4):924-937. PubMed ID: 35046095 [TBL] [Abstract][Full Text] [Related]
11. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Liang SQ; Bührer ED; Berezowska S; Marti TM; Xu D; Froment L; Yang H; Hall SRR; Vassella E; Yang Z; Kocher GJ; Amrein MA; Riether C; Ochsenbein AF; Schmid RA; Peng RW Oncogene; 2019 Jan; 38(5):622-636. PubMed ID: 30171261 [TBL] [Abstract][Full Text] [Related]
13. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers. Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura S; Mzannar Y; Azar I; Beal E; Tobon M; Kim S; Beydoun R; Baloglu E; Senapedis W; El-Rayes B; Philip PA; Mohammad RM; Shields AF; Al-Hallak MN; Azmi AS bioRxiv; 2023 Mar; ():. PubMed ID: 37034616 [TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196 [TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. Boumelha J; de Castro A; Bah N; Cha H; de Carné Trécesson S; Rana S; Tomaschko M; Anastasiou P; Mugarza E; Moore C; Goldstone R; East P; Litchfield K; Lee SH; Molina-Arcas M; Downward J Cancer Res; 2024 Jul; 84(14):2231-2246. PubMed ID: 38635884 [TBL] [Abstract][Full Text] [Related]
16. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis. Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-Induced Metabolic and Oxidative Stress. Hong BJ; Park WY; Kim HR; Moon JW; Lee HY; Park JH; Kim SK; Oh Y; Roe JS; Kim MY Cancer Res; 2019 Nov; 79(22):5849-5859. PubMed ID: 31506334 [TBL] [Abstract][Full Text] [Related]
18. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752 [TBL] [Abstract][Full Text] [Related]
19. c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Sanclemente M; Francoz S; Esteban-Burgos L; Bousquet-Mur E; Djurec M; Lopez-Casas PP; Hidalgo M; Guerra C; Drosten M; Musteanu M; Barbacid M Cancer Cell; 2018 Feb; 33(2):217-228.e4. PubMed ID: 29395869 [TBL] [Abstract][Full Text] [Related]
20. IκB Kinase α Is Required for Development and Progression of Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]